ホームFLNA • BMV
add
Filana Therapeutics Inc
市場ニュース
財務情報
損益計算書
収益
純利益
| (USD) | 2025年12月info | 前年比変化率 |
|---|---|---|
収益 | — | — |
営業費用 | 569.90万 | -36.37% |
純利益 | -1253.90万 | 54.56% |
純利益率 | — | — |
1 株当たりの収益 | — | — |
EBITDA | -918.50万 | 68.57% |
実効税率 | — | — |
貸借対照表
総資産
負債総額
| (USD) | 2025年12月info | 前年比変化率 |
|---|---|---|
現金および短期投資 | 9550.20万 | -25.72% |
総資産 | 1.18億 | -24.87% |
負債総額 | 4395.20万 | 271.56% |
純資産 | 7440.30万 | — |
発行済み株式 | 4830.79万 | — |
帳簿価格 | 19.97 | — |
総資産利益率 | -19.25% | — |
資本利益率 | -30.62% | — |
キャッシュ フロー
現金の純増減額
| (USD) | 2025年12月info | 前年比変化率 |
|---|---|---|
純利益 | -1253.90万 | 54.56% |
営業キャッシュ フロー | -974.80万 | 84.09% |
投資キャッシュ フロー | -50.10万 | -778.95% |
財務キャッシュ フロー | -32.90万 | -135.84% |
現金の純増減額 | -1057.80万 | 82.49% |
フリー キャッシュ フロー | -431.90万 | 64.46% |
概要
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam, an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to company, Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. The DOJ dropped the fraud charges against Wang shortly before trial was scheduled to begin in October 2025 without giving a reason. Wikipedia
設立
1998
本社所在地
従業員数
19
